

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5

1. Name and Address of Reporting Person * <u>Shustov Andrei</u> (Last) (First) (Middle) <u>C/O COLLECTAR BIOSCIENCES, INC.</u> <u>100 CAMPUS DRIVE</u> (Street) <u>FLORHAM NJ 07932</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/15/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>Collectar Biosciences, Inc. [CLRB]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Senior Vice President, Medical</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	---	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>7,181.7</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Amount or Number of Shares		
		Title			

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

/s/ Christina Blakley, Attorney-in-
fact for Andrei Shustov 03/16/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue and Allen Kogan, each acting singly, to prepare, execute and file on the undersigned's behalf a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the U.S. Securities and Exchange Commission (the "SEC") of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation thereunder.

This Statement further confirms that the undersigned has authorized and designated Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the SEC as a result of the undersigned's ownership of or transactions in securities of Collectar Biosciences, Inc.

The authority of Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue, Allen Kogan, Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Collectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue, Allen Kogan, Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Collectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated: March 13, 2023

Signed: /s/ Andrei Shustov

Print Name: Andrei Shustov, M.D.
